Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) just unveiled an announcement.
Hemogenyx Pharmaceuticals has submitted its Annual IND Report to the FDA for its HG-CT-1 CAR-T cell therapy, aimed at treating relapsed or refractory acute myeloid leukemia (AML). This report marks a significant milestone in the clinical development of HG-CT-1, highlighting the company’s commitment to regulatory compliance and transparent communication with stakeholders. The report includes updates on the clinical study’s progress, quality data, and future investigational plans, reinforcing Hemogenyx’s dedication to advancing potentially life-saving therapies for AML patients.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals is a publicly traded clinical-stage biopharmaceutical company headquartered in London, with US subsidiaries in New York City. The company focuses on developing new medicines and treatments for blood and autoimmune diseases, aiming to expand the curative potential of bone marrow transplantation for patients with otherwise incurable life-threatening conditions. Hemogenyx is advancing several product candidates and a platform technology for novel product development.
YTD Price Performance: -52.16%
Average Trading Volume: 32,204
Technical Sentiment Signal: Buy
Current Market Cap: £7.92M
Learn more about HEMO stock on TipRanks’ Stock Analysis page.